US FDA grants first rare pediatrics disease priority review voucher
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has for the first time granted a pharmaceutical company a rare pediatric disease priority review voucher, an incentive program created under the Food and Drug Safety and Innovation Act to encourage the development of new drugs and biologics for pediatric diseases considered rare1,2.